Praxis Precision Medicines, Inc. PRAX 深 沪
等待开盘 01-28 09:30:00 美东时间
314.75
+20.710
+7.04%
华盛通- 最 高315.906
- 今 开290.00
- 成交量 60.06万股
- 最 低 289.50
- 昨 收 294.04
- 总市值 66.25亿
- 52周最高 326.91
- 市盈率 静 --
- 换手率 2.85%
- 52周最低 26.70
- 委 比 58.25%
- 总股本 2104.96万
- 历史最高 914.265
- 量 比 1.06
- 振 幅 8.98%
- 历史最低 11.85
- 每 手 1
- 风险率 87.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $95
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $83 to $95.
01-12 21:54
Praxis Precision prices $575M stock offering at $260
Clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders, Praxis Precision Medicines (PRAX) priced its underwritte...
01-07 12:48
Praxis Precision Medicines announces proposed public stock offering
Praxis Precision Medicines (PRAX) announced a proposed public offering of its common stock and, for certain investors, pre-funded warrants in lieu of common stock. All securities in the offering will ...
01-07 05:09
Praxis Precision Medicines Announces Proposed Public Offering; No Terms Disclosed
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by
01-07 05:05
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Praxis Precision Medicines announced a proposed public offering of its common stock and pre-funded warrants to certain investors. The offering includes an option for underwriters to purchase additional shares. Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities are leading the offering. The offering is subject to market conditions and SEC filing.
01-06 21:03
美股牛股 | Sidus Space涨超33%，完成发行1620万美元股份；DigitalBridge涨近10%
Sidus Space涨超33%，完成发行1620万美元股份，此前获国防部合同；SLS涨超16%，关键实验取得积极进展；DigitalBridge涨近10%，获软银40亿美元收购>>
2025-12-30 14:43
美股大行评级 | 潜在涨幅908.06%！Piper Sandler首予Palisade Bio(PALI)"超配"评级，目标价25美元
今日重点评级关注：Needham：维持Autolus Therapeutics"买入"评级，目标价从10美元升至11美元；BTIG：维持Praxis Precision Medicine"买入"评级，目标价从507美元升至843美元
2025-12-30 10:04
BTIG将PRXV列为2026年首选标的 目标价从507美元上调至843美元
临床阶段生物制药公司Praxis Precision Medicines（PRXV）周一盘前上涨逾2%，此前BTIG将其股票列为2026年首选标的，并上调了...
2025-12-29 21:50
Praxis Wins FDA Breakthrough Status for Ulixacaltamide
The latest announcement is out from Praxis Precision Medicines ( ($PRAX) ). On ...
2025-12-29 21:28
